SEER Stock Overview
A life sciences company, develops and commercializes products to decode the biology of the proteome. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Seer, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.80 |
| 52 Week High | US$2.63 |
| 52 Week Low | US$1.56 |
| Beta | 1.62 |
| 1 Month Change | -8.16% |
| 3 Month Change | -25.31% |
| 1 Year Change | 2.27% |
| 3 Year Change | -85.02% |
| 5 Year Change | n/a |
| Change since IPO | -96.81% |
Recent News & Updates
Recent updates
Proteograph Product Suite And Thermo Fisher Partnership Will Open Markets
Apr 05 Strategic investments in commercial infrastructure and leadership aim to support revenue growth through increased productivity and sales effectiveness.We're Keeping An Eye On Seer's (NASDAQ:SEER) Cash Burn Rate
Apr 27
Seer, Inc. (NASDAQ:SEER) Just Reported, And Analysts Assigned A US$7.00 Price Target
Mar 02Newsflash: Seer, Inc. (NASDAQ:SEER) Analysts Have Been Trimming Their Revenue Forecasts
Nov 17We're Not Very Worried About Seer's (NASDAQ:SEER) Cash Burn Rate
May 19Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth
Feb 06Analysts Have Lowered Expectations For Seer, Inc. (NASDAQ:SEER) After Its Latest Results
Nov 11Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans
Sep 15Seer stock tumbles aftermarket despite in-line Q2 earnings
Aug 09Companies Like Seer (NASDAQ:SEER) Are In A Position To Invest In Growth
Jun 02We Think Seer (NASDAQ:SEER) Can Afford To Drive Business Growth
Jan 17Shareholder Returns
| SEER | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 8.4% | -11.1% | -10.1% |
| 1Y | 2.3% | -30.0% | -3.8% |
Return vs Industry: SEER exceeded the US Life Sciences industry which returned -30% over the past year.
Return vs Market: SEER exceeded the US Market which returned -3.8% over the past year.
Price Volatility
| SEER volatility | |
|---|---|
| SEER Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 9.7% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: SEER has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SEER's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 134 | Omid Farokhzad | seer.bio |
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes.
Seer, Inc. Fundamentals Summary
| SEER fundamental statistics | |
|---|---|
| Market cap | US$107.01m |
| Earnings (TTM) | -US$86.60m |
| Revenue (TTM) | US$14.17m |
7.6x
P/S Ratio-1.2x
P/E RatioIs SEER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEER income statement (TTM) | |
|---|---|
| Revenue | US$14.17m |
| Cost of Revenue | US$7.12m |
| Gross Profit | US$7.06m |
| Other Expenses | US$93.65m |
| Earnings | -US$86.60m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 49.79% |
| Net Profit Margin | -611.14% |
| Debt/Equity Ratio | 0% |
How did SEER perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/08 00:28 |
| End of Day Share Price | 2025/04/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Seer, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Rachel Vatnsdal Olson | J.P. Morgan |
| Tejas Savant | Morgan Stanley |